A decades-old drug used to lower cholesterol levels in the blood has been shown to reduce the progression of vision-robbing retinopathy in people with diabetes.
The first reveal of clinical data with Eli Lilly’s injectable triple receptor agonist for obesity suggests that the company could have a big winner on its hands if the dru